Mark Iwicki - Pulmatrix Insider

PULM -- USA Stock  

USD 0.49  0.0002  0.041%

  Chairman
Mr. Mark Iwicki is Independent Chairman of the Board of Pulmatrix, Inc. Mr. Iwicki has served as chairman of the Board and as a director of our Company since his appointment in December 2015. Mr. Iwicki currently serves as chairman of the board of directors and chief executive officer of Kala Pharmaceuticals. Prior to joining Kala, he was president and chief executive officer of Civitas Therapeutics, Inc., which was acquired by Acorda Therapeutics, Inc. in October 2014. Prior to joining Civitas, he served as president and chief executive officer at Blend Therapeutics, Inc., or Blend, from December 2012 to January 2014. Prior to Blend, Mr. Iwicki was president and chief executive officer of Sunovion Pharmaceuticals Inc., or Sunovion. Mr. Iwicki was at SepracorSunovion from October 2007 to June 2012. Prior to joining Sepracor Inc., Mr. Iwicki was at Novartis Pharmaceuticals Corporationrationration from March 1998 to October 2007, where he was vice president and business unit head. Before that, he held management positions at Astra Merck Inc. and Merck Co., Inc. In addition to serving on our Board, Mr. Iwicki is currently a director at Kala Pharmaceuticals, Merus, Aimmune Therapeutics, Nimbus Therapeutics, Taris Biomedical and Oxeia Biopharmaceuticals. He previously served on the boards of Civitas, Sunovion and Blend, all privately held companies
Age: 50  Chairman Since 2015  MBA    
781-357-2333  http://pulmatrix.com
Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University.

Management Efficiency

The company has return on total asset (ROA) of (65.98) % which means that it has lost $65.98 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (168.96) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.52 M in liabilities with Debt to Equity (D/E) ratio of 33.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix has Current Ratio of 0.32 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 24 people.Pulmatrix (PULM) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 24 people. Pulmatrix was previously known as PULMATRIX INC and was traded on BATS Exchange under the symbol RTGN. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.

Pulmatrix Leadership Team

Terrance McGuire, Director
Matthew Sherman, Director
David Hava, Chief Scientific Officer
Akihisa Akao, Director
James Roach, Chief Medical Officer
Michael Higgins, Director
Steven Gillis, Director
Jean Sung, Vice President - Pharmaceutical Development
William Duke, CFO, Principal Financial Officer & Principal Accounting Officer
Robert Clarke, CEO and President and Director
Scott Rocklage, Director
Kurt Graves, Director
Richard Conley, Independent Director
Mark Iwicki, Chairman of the Board
Amit Munshi, Director
Gregory French, Independent Director
David JD, Advisor

Stock Performance Indicators

Did you try this?

Run Analyst Recommendations Now
   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Analyst Recommendations
Currently Active Assets on Macroaxis
MSFT   
Purchased over 20 shares of
a day ago
Traded for 106.27
F   
Purchased over 200 shares of
a day ago
Traded for 10.56
GM   
Purchased over 70 shares of
a day ago
Traded for 39.4
GOOG   
Purchased few shares of
a day ago
Traded for 1184.91
C   
Purchased over 40 shares of
a day ago
Traded for 69.22
Additionally take a look at Your Equity Center. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">